Home / Health / Rectal Cancer Breakthrough: No Tumors Found After Treatment
Rectal Cancer Breakthrough: No Tumors Found After Treatment
28 Aug
Summary
- GSK's Jemperli shows no detectable rectal tumors for one year.
- FDA grants priority review, potentially avoiding chemo and surgery.
- Trial shows sustained complete responses, improving quality of life.
GSK's Jemperli has been granted priority review by the U.S. Food and Drug Administration (FDA), based on trial data showing no detectable rectal tumors for at least one year in a substantial number of patients. This signifies a potential historic shift, offering selected patients the chance to avoid chemotherapy, radiation, and surgery.
The FDA's review is driven by the AZUR-1 phase II trial, which evaluated Jemperli as a standalone treatment for specific rectal cancers. The study met its primary objective, demonstrating clinical complete responses lasting at least 12 months. These results suggest a significant improvement compared to the historical standard of care.
For decades, treatment for this rectal cancer subtype has involved chemotherapy, radiation, and surgery. While curative, these treatments often lead to life-altering complications and can impact quality of life. Jemperli could become the first immunotherapy approved to help some patients eliminate or delay the need for these invasive procedures.
The trial enrolled 154 patients who received nine cycles of Jemperli over six months. Interim safety findings were consistent with the drug's established profile. The FDA's decision deadline is set for February 2027, but expedited review pathways could lead to an earlier ruling. International approvals are also being coordinated through Project Orbis.
